Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease, counteracts NSAID-induced intestinal damage
In February of 2020, the FDA began to crack down on this practice by putting out an advisory
Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat
Report limitations clearly: State when a study lacks comprehensive toxicology endpoints, sex-specific analysis, long-duration exposure, reproductive endpoints, hematology, immunology, or genotoxicity assessment
Additionally, it may have anti-aging properties, rejuvenating cells and supporting skin health